Dr. George Kuchel, director, UConn Center on Aging and chief, Geriatrics, UConn Health has the honor of being elected to the Academy for Health and Lifespan Research (AHLR).
AHLR is the leading organization comprising the world’s most esteemed scientists dedicated to studying the mechanisms of aging and developing interventions to slow and reverse the process. Its members are elected annually based on their significant scientific contributions and commitment to the community.
The mission of AHLR encompasses several key objectives, including transforming societal perceptions about healthy aging, promoting research for longer and healthier life, attracting talent to the longevity research field, educating the public on science and healthy lifestyles, and advocating for policy changes to recognize aging as a treatable condition.
The Academy is comprised of an elite group of 60 world-renowned researchers, scientists and clinicians, all united toward making breakthroughs in longevity and healthy aging both accelerated and accessible. The members are elected to this prestigious society and participate in its invitation only annual meeting. The annual meeting includes elected members and invited guests from the world of biotechnology, financial investment and health policy.
“As a non-profit we empower scientists to develop drugs and treatments by acting as a catalyst, an idea pipeline, and a convening body for talent and technology,” says David Sinclair, PhD, AO president, The Academy for Health and Lifespan Research. “Our efforts will accelerate the current brilliant work being done in laboratories around the world, bringing the level of attention and funding that longevity initiatives deserve and demand.”
By advancing innovative collaboration between the world’s leading scientists, laboratories, academic institutions and drug companies, the Academy’s vision is to envision a world where breakthroughs in longevity research are not just accelerated but more importantly, made accessible to all.
“I am honored to be elected. My involvement reflects the maturation and national prominence of our institutional efforts involving the discovery and validation of new classes of drugs called gerotherapeutics,” says Kuchel.
